Haemonetics Co. (NYSE:HAE) Shares Sold by Swiss National Bank

Swiss National Bank lessened its position in Haemonetics Co. (NYSE:HAE) by 0.4% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 99,500 shares of the medical instruments supplier’s stock after selling 400 shares during the period. Swiss National Bank’s holdings in Haemonetics were worth $7,998,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Quarry LP acquired a new position in shares of Haemonetics in the second quarter valued at approximately $39,000. Daiwa Securities Group Inc. purchased a new stake in Haemonetics in the second quarter valued at approximately $82,000. Canada Pension Plan Investment Board purchased a new stake in Haemonetics in the second quarter valued at approximately $83,000. Nisa Investment Advisors LLC grew its holdings in Haemonetics by 124.2% in the third quarter. Nisa Investment Advisors LLC now owns 1,141 shares of the medical instruments supplier’s stock valued at $92,000 after purchasing an additional 632 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Haemonetics in the second quarter valued at approximately $140,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on HAE. BTIG Research began coverage on shares of Haemonetics in a report on Tuesday, September 10th. They issued a “buy” rating and a $112.00 target price for the company. JMP Securities restated a “market outperform” rating and issued a $125.00 target price on shares of Haemonetics in a report on Tuesday, August 13th. CL King began coverage on shares of Haemonetics in a report on Friday, September 13th. They issued a “buy” rating and a $116.00 target price for the company. Raymond James upgraded shares of Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 price objective for the company in a research note on Friday, November 8th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $112.00 price objective on shares of Haemonetics in a research note on Friday, November 15th. Three investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $107.88.

Haemonetics Price Performance

Shares of HAE stock opened at $88.49 on Tuesday. The company has a market capitalization of $4.44 billion, a PE ratio of 36.72, a price-to-earnings-growth ratio of 1.33 and a beta of 0.32. The firm has a fifty day simple moving average of $78.99 and a 200-day simple moving average of $82.29. The company has a current ratio of 3.49, a quick ratio of 2.09 and a debt-to-equity ratio of 1.39. Haemonetics Co. has a twelve month low of $70.25 and a twelve month high of $97.97.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.03. The business had revenue of $345.50 million during the quarter, compared to the consensus estimate of $342.57 million. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. The business’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.99 earnings per share. Equities research analysts anticipate that Haemonetics Co. will post 4.59 earnings per share for the current fiscal year.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.